JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267093

Human CFHR3 (Complement factor H-related protein 3) knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CFHR3 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 2 bp insertion in exon 2 and 4 bp deletion in exon 2.

View Alternative Names

CFHR3, Complement factor H-related protein 3, DOWN16, FHR3_HUMAN, H factor-like protein 3

2 Images
Sanger Sequencing - Human CFHR3 (Complement factor H-related protein 3) knockout A549 cell line (AB267093)
  • Sanger seq

Unknown

Allele-1 : 4 bp deletion in exon2

Sanger Sequencing - Human CFHR3 (Complement factor H-related protein 3) knockout A549 cell line (AB267093)
  • Sanger seq

Unknown

Allele-2 : 2 bp insertion in exon 2.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp insertion in exon 2 and 4 bp deletion in exon 2

Disease

Carcinoma

Product details

Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267093-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267093 Human CFHR3 (Complement factor H-related protein 3) knockout A549 cell line", "number":"AB267093-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267093-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267093 Human CFHR3 (Complement factor H-related protein 3) knockout A549 cell line", "number":"AB267093-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CFHR3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Complement factor H-related protein 3 (CFHR3) also known as FHR-3 plays a role in modulating the complement system. This protein has a mass of approximately 42 kDa. CFHR3 is expressed in tissues like the liver and can be found circulating in the plasma. It belongs to the factor H protein family which participates in maintaining immune homeostasis by regulating complement activation.
Biological function summary

CFHR3 acts as an antagonist to complement factor H by competing for binding sites on target surfaces and complement components. It does not function as a standalone protein but interacts closely within a family that includes CFH and other complement factor H-related proteins. CFHR3 can potentially form complexes with similar proteins to help finely tune the activity of the complement system to prevent excessive immune response.

Pathways

CFHR3 is a part of the complement cascade system specifically the alternative pathway. It contributes to the negative regulation of this pathway which is important for preventing overactivation that could harm host tissues. The protein influences the binding of complement proteins like C3b an essential component in the complement cascade and interacts with other factor H-related proteins such as CFHR1 to modulate pathway activities.

CFHR3's regulatory role connects it to conditions like atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). In aHUS mutations or deletions in CFHR3 sometimes in conjunction with CFHR1 can lead to uncontrolled complement activation contributing to disease progression. Similarly variations in CFHR3's sequence can affect AMD risk often in association with other complement regulatory proteins including CFH indicating its significant position in disease susceptibility through its regulatory function within the immune system.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com